Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Takaaki Fujii
Observed name:
TAKAAKI FUJII
Institutions:
Nippon Medical School Hospital,
Nippon Medical School
Observed institutions:
Gunma University,
Nippon Medical School Hospital,
Chiba Hokusou Hospital,
Gunma University Hospital,
Nippon Medical School
ORCID:
0000-0001-8357-391X
Observed ORCID:
0000-0001-8357-391X
OpenAlex ID:
A5112929231
Effectiveness of Scalp-cooling Therapy for Preventing Chemotherapy-induced Alopecia in Patients With Breast Cancer: A Prospective Observational Study Focusing on Scalp, Eyebrow, and Eyelash Hair Loss
2025
·
TAKAAKI FUJII
, KEI ICHIBA
, et al.
·
In Vivo
·
6
Characteristics of Patients With Metastatic Breast Cancer Who Survived more than 10 Years
2022
·
MAMI KIKUCHI
, TAKAAKI FUJII
, et al.
·
Anticancer Research
·
2
PDF
Plasma concentrations of doxorubicin and cyclophosphamide during anthracycline-based chemotherapy in a pregnant breast cancer patient: evaluation of gestational changes
2026
·
Sohei Ohshima
, Takuya Araki
, et al.
·
Cancer Chemotherapy and Pharmacology
·
1
Clinical Significance of FAM83G in Breast Cancer: Association With Triple-negative Subtype and Prognosis
2024
·
TAKAKO IKEDA
, CHIKAKO KANNO HONDA
, et al.
·
Anticancer Research
·
1
Preoperative prevalence and risk factors of venous thromboembolism in patients with breast cancer: A retrospective cohort analysis
2026
·
Takaaki Fujii
, Erika Suzuki
, et al.
·
Research Square
PDF
Efficacy of xeno-free induced mesenchymal stem/stromal cells in enhancing autologous fat graft survival
2026
·
Hideharu Nakamura
, Takaya Makiguchi
, et al.
·
Breast Cancer
PDF
Ideas for Breast Cancer Screening Using Digital Technology: ~From the perspective of a physician in the field responsible for breast cancer screening~
2025
·
Keiko Tanabe
, Sasagu Kurozumi
, et al.
·
Nihon Nyugan Kenshin Gakkaishi (Journal of Japan Association of Breast Cancer Screening)
EPIK-B6: A phase 2, open-label, 2-part, multicenter study of alpelisib in combination with fulvestrant for men and postmenopausal women with PIK3CA mutation HR–positive, HER2-negative, advanced breast cancer, which progressed on/after aromatase inhibitor treatment in Japan.
2023
·
Hiroji Iwata
, Naoki Niikura
, et al.
·
Journal of Clinical Oncology
PDF
Abstract P2-12-23: Changes in 18F-FDG-PET uptake after the first course of DTX reflect response to preoperative chemotherapy and prognosis in breast cancer
2022
·
Tomoko Hirakata
, Yasuhiro Yanagita
, et al.
·
Cancer Research
Show more works
View as search
Works count:
9
Citation count:
10
H-index:
2
I10-index:
Year
Topic
Type